ArticleReviews in urology2009
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.
Article in Reviews in urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.Asian journal of andrology · 2013Pooled it
- A comparative study of mirabegron versus doxazosin in improving ureteral stent-related dysfunction.World journal of urology · 2025Trial
- Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.International urology and nephrology · 2011Trial
- The Effect of Long-Term Tamsulosin Monotherapy and Tamsulosin - Dutasteride Combination Therapy on PKC-α Enzyme Expression in Prostate Stromal Tissue.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2023Article
- Male Lower Urinary Tract Dysfunction: An Underrepresented Endpoint in Toxicology Research.Toxics · 2022Review
- Beneficial Extracardiac Effects of Cardiovascular Medications.Current cardiology reviews · 2022Review
- Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review.BJUI compass · 2021Review
- Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.European journal of clinical pharmacology · 2018Article
- Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications.Prostate international · 2017Article
- Impact of oral capsule ofJournal of renal injury prevention · 2017Article
- Isoform-specific dynamic translocation of PKC by α1-adrenoceptor stimulation in live cells.Biochemical and biophysical research communications · 2015Article
- Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.Current urology reports · 2014Review
- The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?Turkish journal of urology · 2014Article
- Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration.The Journal of clinical investigation · 2013Article
- Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial.Iranian Red Crescent medical journal · 2013Article
- Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it.Therapeutic advances in urology · 2012Article
- Update on the sexual impact of treatment for benign prostatic hyperplasia.Current urology reports · 2012Review
- Management of urinary incontinence.P & T : a peer-reviewed journal for formulary management · 2012Article
- Complications of cataract surgery in patients with BPH treated with alpha 1A-blockers.Central European journal of urology · 2011Review
- Silodosin in the treatment of benign prostatic hyperplasia.Drug design, development and therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male lower urinary tract symptoms (LUTS) are one of the most common causes for a consultation with a health care provider, and one of the most common causes of male LUTS is benign prostatic hyperplasia (BPH). In recent decades, medical therapy has established itself as viable and cost effective for the majority of men. For the treatment of male LUTS in the United States, the 5 currently available alpha-adrenergic receptor blockers are alfuzosin, doxazosin, silodosin, terazosin, and tamsulosin. alpha-Blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit an early onset of efficacy (within less than 1 week) with regard to both symptoms and flow rate improvement, maintain such improvements in open-label and controlled trials for up to 5 years, and have been shown to prevent symptomatic progression.
Indexed as
Identifiers
20126606PMC2812889W78871405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.